View table: Medicines
Table structure:
- generic - String
- brand - String
- structure - File
- classes - List of String, delimiter: ,
- mechanism - String
- uses - String
- starting_dose - String
- preparations - String
- fda_max - String
- pill_id - Text
- routes - List of String, delimiter: ,
- onset - String
- duration - String
- halflife - String
- bioavailability - String
- pregnancy - String
- legal - String
This table has 732 rows altogether.
| Page | generic | brand | structure | classes | mechanism | uses | starting dose | preparations | fda max | pill id | routes | onset | duration | halflife | bioavailability | pregnancy | legal |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,4-Butanediol (edit) | 1,4-Butanediol | GABAergic • Research material | Prodrug of GHB | ||||||||||||||
| 1B-LSD (edit) | 1B-LSD | Research material • Lysergamide • Classic Psychedelic | Prodrug of LSD; 5-HT2A agonist | ||||||||||||||
| 1cP-LSD (edit) | 1cP-LSD | Research material • Lysergamide • Classic Psychedelic | Prodrug of LSD; 5-HT2A agonist | ||||||||||||||
| 1P-LSD (edit) | 1P-LSD | Research material • Lysergamide • Classic Psychedelic | Prodrug of LSD; 5-HT2A agonist | ||||||||||||||
| 1V-LSD (edit) | 1V-LSD | Research material • Lysergamide • Classic Psychedelic | Prodrug of LSD; 5-HT2A agonist | ||||||||||||||
| 2-AI (edit) | 2-AI | Research material • Stimulant | Alpha-methylated amphetamine analogue; norepinephrine releasing agent | ||||||||||||||
| 2-FA (edit) | 2-FA | Research material • Amphetamine • Stimulant | Monoamine releasing agent | ||||||||||||||
| 2-FDCK (edit) | 2-FDCK | Research material • Dissociative | NMDA antagonist; fluorinated ketamine analogue | ||||||||||||||
| 2-FMA (edit) | 2-FMA | Research material • Amphetamine • Stimulant | Monoamine releasing agent | ||||||||||||||
| 25B-NBOH (edit) | 25B-NBOH | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist | ||||||||||||||
| 25B-NBOMe (edit) | 25B-NBOMe | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist; no oral activity | ||||||||||||||
| 25C-NBOH (edit) | 25C-NBOH | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist | ||||||||||||||
| 25C-NBOMe (edit) | 25C-NBOMe | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist | ||||||||||||||
| 25I-NBOH (edit) | 25I-NBOH | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist | ||||||||||||||
| 25I-NBOMe (edit) | 25I-NBOMe | Research material • Phenethylamine • Classic Psychedelic | Extremely potent 5-HT2A agonist; vasoconstrictor | ||||||||||||||
| 25N-NBOMe (edit) | 25N-NBOMe | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 2C-B (edit) | 2C-B | Nexus, Eroxan (historical, late-1980s through mid-1990s) | Psychedelic • Phenethylamine • 2C-x series | 5-HT2A partial agonist | Oral • insufflated • PR | 45-75 min (oral) | 4-8 h | Not well characterized | Not well characterized | Not established | [[USLegal:DEA Schedule I|Schedule I]] (United States) | ||||||
| 2C-B-FLY (edit) | 2C-B-FLY | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 2C-C (edit) | 2C-C | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 2C-D (edit) | 2C-D | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist; milder than other 2C-x | ||||||||||||||
| 2C-E (edit) | 2C-E | Research material • Phenethylamine • Classic Psychedelic | Potent 5-HT2A agonist | ||||||||||||||
| 2C-I (edit) | 2C-I | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 2C-P (edit) | 2C-P | Research material • Phenethylamine • Classic Psychedelic | Very potent 5-HT2A agonist; long duration | ||||||||||||||
| 2C-T-2 (edit) | 2C-T-2 | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 2C-T-7 (edit) | 2C-T-7 | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist; MAO inhibitor | ||||||||||||||
| 3,4-CTMP (edit) | 3,4-CTMP | Research material • Phenidate • Stimulant | Potent dopamine/norepinephrine reuptake inhibitor | ||||||||||||||
| 3-FA (edit) | 3-FA | Research material • Amphetamine • Stimulant | Monoamine releasing agent | ||||||||||||||
| 3-FMA (edit) | 3-FMA | Research material • Amphetamine • Stimulant | Monoamine releasing agent | ||||||||||||||
| 3-HO-PCE (edit) | 3-HO-PCE | Research material • Dissociative | NMDA antagonist; opioid agonist | ||||||||||||||
| 3-HO-PCP (edit) | 3-HO-PCP | Research material • Dissociative | NMDA antagonist; potent opioid agonist | ||||||||||||||
| 3-MeO-PCE (edit) | 3-MeO-PCE | Research material • Dissociative | NMDA antagonist; sigma receptor agonist | ||||||||||||||
| 3-MeO-PCP (edit) | 3-MeO-PCP | Research material • Dissociative | NMDA antagonist; sigma receptor agonist; dopaminergic | ||||||||||||||
| 3-MMC (edit) | 3-MMC | Research material • Cathinone • Stimulant | Monoamine releasing agent | ||||||||||||||
| 4-AcO-DET (edit) | 4-AcO-DET | Research material • Tryptamine • Classic Psychedelic | Prodrug of 4-HO-DET; 5-HT2A agonist | ||||||||||||||
| 4-AcO-DiPT (edit) | 4-AcO-DiPT | Research material • Tryptamine • Classic Psychedelic | Prodrug of 4-HO-DiPT; 5-HT2A agonist | ||||||||||||||
| 4-AcO-DMT (edit) | 4-AcO-DMT | Research material • Tryptamine • Classic Psychedelic | Prodrug of psilocin; 5-HT2A agonist | ||||||||||||||
| 4-AcO-MET (edit) | 4-AcO-MET | Research material • Tryptamine • Classic Psychedelic | Prodrug of 4-HO-MET; 5-HT2A agonist | ||||||||||||||
| 4-AcO-MiPT (edit) | 4-AcO-MiPT | Research material • Tryptamine • Classic Psychedelic | Prodrug of 4-HO-MiPT; 5-HT2A agonist | ||||||||||||||
| 4-FA (edit) | 4-FA | Research material • Amphetamine • Stimulant • Empathogen | Monoamine releasing agent; serotonergic at higher doses | ||||||||||||||
| 4-FMA (edit) | 4-FMA | Research material • Amphetamine • Stimulant | Monoamine releasing agent | ||||||||||||||
| 4-HO-DET (edit) | 4-HO-DET | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-HO-DiPT (edit) | 4-HO-DiPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-HO-DPT (edit) | 4-HO-DPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-HO-EPT (edit) | 4-HO-EPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-HO-MET (edit) | 4-HO-MET | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-HO-MiPT (edit) | 4-HO-MiPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 4-MeO-PCP (edit) | 4-MeO-PCP | Research material • Dissociative | NMDA antagonist | ||||||||||||||
| 4F-EPH (edit) | 4F-EPH | Research material • Phenidate • Stimulant | Dopamine/norepinephrine reuptake inhibitor | ||||||||||||||
| 4F-MPH (edit) | 4F-MPH | Research material • Phenidate • Stimulant | Dopamine/norepinephrine reuptake inhibitor | ||||||||||||||
| 5,6-MDO-DMT (edit) | 5,6-MDO-DMT | Research material • Tryptamine | 5-HT2A agonist | ||||||||||||||
| 5-APB (edit) | 5-APB | Empathogen • Benzofuran | Serotonin releasing agent; 5-HT2A agonist | ||||||||||||||
| 5-HTP (edit) | 5-HTP | Nootropic • Oneirogen | Serotonin precursor; 5-hydroxytryptophan | ||||||||||||||
| 5-MAPB (edit) | 5-MAPB | Empathogen • Benzofuran | Serotonin releasing agent; 5-HT2A agonist | ||||||||||||||
| 5-MeO-DALT (edit) | 5-MeO-DALT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist; sigma-1 agonist | ||||||||||||||
| 5-MeO-DiPT (edit) | 5-MeO-DiPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 5-MeO-DMT (edit) | 5-MeO-DMT | Research material • Tryptamine • Classic Psychedelic | Potent 5-HT2A agonist; sigma-1 agonist | ||||||||||||||
| 5-MeO-MiPT (edit) | 5-MeO-MiPT | Research material • Tryptamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| 5F-AKB48 (edit) | 5F-AKB48 | Synthetic cannabinoid • Research material | CB1/CB2 agonist | ||||||||||||||
| 5F-PB-22 (edit) | 5F-PB-22 | Synthetic cannabinoid • Research material | CB1/CB2 agonist | ||||||||||||||
| 6-APB (edit) | 6-APB | Empathogen • Benzofuran | Serotonin releasing agent; 5-HT2A agonist | ||||||||||||||
| 6-APDB (edit) | 6-APDB | Empathogen • Benzofuran | Serotonin releasing agent | ||||||||||||||
| 7-Hydroxymitragynine (edit) | 7-Hydroxymitragynine | Opioid • Botanical | Potent mu-opioid receptor agonist | ||||||||||||||
| AB-FUBINACA (edit) | AB-FUBINACA | Synthetic cannabinoid • Research material | CB1/CB2 agonist | ||||||||||||||
| Acacia confusa (edit) | Acacia confusa | Botanical | DMT-containing plant used in psychedelic preparations | ||||||||||||||
| Acamprosate (edit) | Acamprosate | Campral | Addiction medicine | NMDA antagonist; GABAA modulator | |||||||||||||
| Acetaminophen (edit) | Acetaminophen (paracetamol, APAP) | Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence | [[:Category:Analgesics|Non-opioid analgesic]] • [[:Category:Antipyretics|Antipyretic]] | '"`UNIQ--vote-000006A2-QINU`"', '"`UNIQ--vote-000006A3-QINU`"', '"`UNIQ--vote-000006A4-QINU`"' | 325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours | 325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines | 4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use | Oral • rectal • IV | PO: 30-60 minutes; IV: minutes | 4-6 hours | 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion'"`UNIQ--ref-000006A5-QINU`"' | ~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"' | Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | OTC and [[USLegal:Prescription only|Rx-only]] (IV, combination products) in US | |||
| Acetylfentanyl (edit) | Acetylfentanyl | Opioid • Research material | Mu-opioid receptor agonist; fentanyl analogue | ||||||||||||||
| Acyclovir (edit) | Acyclovir | Zovirax | [[:Category:Antivirals|Antiviral]] • [[:Category:Nucleoside_analogs|Nucleoside analog]] • [[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]] | '"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"' | Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days | 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) | Indication-specific; high-dose IV regimens for encephalitis or disseminated disease | Oral • IV • topical | Symptom relief within 24-48 hours of starting episodic treatment | 8 hours per oral dose | ~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"' | ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' | Widely used in pregnancy for HSV/VZV indications; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | |||
| Adalimumab (edit) | Adalimumab | Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada | [[:Category:TNF_inhibitors|TNF-α inhibitor]] • [[:Category:Biologics|Biologic]] • [[:Category:DMARDs|DMARD]] • [[:Category:Immunosuppressants|Immunosuppressant]] • [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] | '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. | 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week | 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths | 40 mg every week (selected indications); otherwise 40 mg every other week | Subcutaneous | Symptomatic effect within weeks; full response by 12-24 weeks | 2 weeks per dose | ~14 days'"`UNIQ--ref-00001103-QINU`"' | ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' | |||||
| Adrafinil (edit) | Adrafinil | Eugeroic • Nootropic | Prodrug of modafinil | ||||||||||||||
| Aducanumab (edit) | Aduhelm | Anti-amyloid beta (Aβ) monoclonal antibody | Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. | Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. | Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w | Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion | Withdrawn 2024 | IV infusion every 4 weeks | PET Aβ reduction over months | Withdrawn | ~25 days | 100% (IV) | Discontinued/withdrawn | Withdrawn from US market January 2024 | |||
| Agomelatine (edit) | Agomelatine | Valdoxan | Antidepressant | Melatonin receptor agonist; 5-HT2C antagonist | |||||||||||||
| AL-LAD (edit) | AL-LAD | Research material • Lysergamide • Classic Psychedelic | LSD analogue; 5-HT2A agonist | ||||||||||||||
| Albuterol (edit) | Albuterol | Ventolin, ProAir, Proventil, AccuNeb | [[:Category:Beta-2_adrenergic_agonists|Short-acting β2-agonist]] • [[:Category:Bronchodilators|Bronchodilator]] | '"`UNIQ--vote-00000093-QINU`"' At higher doses β2 selectivity is lost, producing β1 effects (tachycardia, tremor) and hypokalemia from intracellular potassium shift'"`UNIQ--ref-00000094-QINU`"'. | '"`UNIQ--vote-00000095-QINU`"', '"`UNIQ--vote-00000096-QINU`"', '"`UNIQ--vote-00000097-QINU`"', '"`UNIQ--vote-00000098-QINU`"' | MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h | MDI 90 mcg/puff; nebulizer solution 0.083% (2.5 mg/3 mL), 0.5%, 0.021%, 0.042%; syrup 2 mg/5 mL; 2 mg, 4 mg tablets; 4 mg, 8 mg ER | 12 inhalations/d (rescue); higher for severe exacerbation under monitoring | Inhaled (MDI • nebulized) • Oral | Inhaled: 5-15 minutes; PO: 30 minutes | 4-6 hours | 4-6 hours (inhaled and PO)'"`UNIQ--ref-00000099-QINU`"' | ~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"' | Preferred SABA in pregnancy; benefits of asthma control outweigh limited risks.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | ||
| ALD-52 (edit) | ALD-52 | Research material • Lysergamide • Classic Psychedelic | 1-acetyl-LSD; prodrug of LSD | ||||||||||||||
| Alendronate (edit) | Alendronate | Fosamax, Binosto | [[:Category:Bisphosphonates|Bisphosphonate (nitrogen-containing)]] • [[:Category:Antiresorptives|Antiresorptive]] • [[:Category:Osteoporosis_medications|Osteoporosis medication]] | '"`UNIQ--vote-000006BE-QINU`"' Drug-holiday concept (3-5 years on, 1-2 years off) emerged from FLEX and long-term safety data balancing fracture protection against atypical femoral fracture and osteonecrosis of the jaw signals'"`UNIQ--ref-000006BF-QINU`"'. | '"`UNIQ--vote-000006C0-QINU`"', '"`UNIQ--vote-000006C1-QINU`"', '"`UNIQ--vote-000006C2-QINU`"' | Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes | 5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto) | 70 mg/week treatment; 40 mg/d for 6 months in Paget's | Oral | Bone marker reduction within weeks; BMD improvement at 1-3 years; fracture-risk reduction documented at 3-5 years | Weeks; bone retention years | Plasma ~3 hours; bone half-life ~10 years'"`UNIQ--ref-000006C3-QINU`"' | <1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"' | Long-term skeletal retention is a concern given the unknown effect on developing fetal bone; generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | ||
| Alfentanil (edit) | Alfentanil | Alfenta | Opioid • Anesthetic adjunct | Potent mu-opioid receptor agonist | |||||||||||||
| Allopurinol (edit) | Allopurinol | Zyloprim, Aloprim (IV) | [[:Category:Xanthine_oxidase_inhibitors|Xanthine oxidase inhibitor]] • [[:Category:Antihyperuricemic_agents|Antihyperuricemic agent]] • [[:Category:Antigout_agents|Antigout agent]] | '"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' | 100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) | 100 mg, 300 mg tablets; IV 500 mg vial | 800 mg/d (rarely needed) | Oral • IV | Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation | 24 hours | 1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' | ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' | Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | |||
| Allylescaline (edit) | Allylescaline | Research material • Phenethylamine • Classic Psychedelic | 5-HT2A agonist | ||||||||||||||
| Almotriptan (edit) | Almotriptan | Axert | Triptan • Migraine medicine | 5-HT1B/1D agonist | |||||||||||||
| Alpha-PHP (edit) | alpha-PHP | Research material • Pyrrolidinophenone • Stimulant | Dopamine and norepinephrine reuptake inhibitor | ||||||||||||||
| Alpha-PVP (edit) | alpha-PVP | Research material • Pyrrolidinophenone • Stimulant | Dopamine and norepinephrine reuptake inhibitor | ||||||||||||||
| Alprazolam (edit) | Alprazolam | Xanax | Benzodiazepine • Triazolobenzodiazepine • Anxiolytic | GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' | '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' | 0.25 mg | 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate | 10 mg/d | * '''0.25 mg:''' white oval scored tablet * '''0.5 mg:''' peach/orange oval scored tablet * '''1 mg:''' blue oval scored tablet * '''2 mg:''' white rectangular bar with three score lines (the "Xanax bar") * '''XR forms:''' film-coated, varying shapes and colors by strength and manufacturer * '''Oral concentrate:''' 1 mg/mL, alcohol-free solution | Oral | 30-60 min (immediate-release); 1-2 h (extended-release) | 6 h (immediate-release); ~11 h (extended-release) | 11-13 h (immediate-release); 11-16 h (extended-release) | 80-90% oral | Category D'"`UNIQ--ref-0000006C-QINU`"' | Schedule IV (US) | |
| Amanita muscaria (edit) | Amanita muscaria | Deliriant • Botanical | Contains muscimol and ibotenic acid | ||||||||||||||
| Amantadine (edit) | Amantadine | Symmetrel | Antiparkinsonian | NMDA antagonist; dopamine releasing agent | |||||||||||||
| Amiodarone (edit) | Amiodarone | Cordarone, Pacerone, Nexterone (IV) | [[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class III)]] • [[:Category:Cardiovascular_agents|Cardiovascular agent]] | '"`UNIQ--vote-00000CB0-QINU`"', '"`UNIQ--vote-00000CB1-QINU`"', '"`UNIQ--vote-00000CB2-QINU`"' | Oral load 800-1600 mg/d in divided doses for 1-3 weeks, then 600-800 mg/d for 1 month, then 200-400 mg/d maintenance; IV 150 mg over 10 min then 1 mg/min for 6 hours then 0.5 mg/min | 100, 200, 400 mg tablets; 50 mg/mL IV (with polysorbate 80 in older formulations causing hypotension); 1.5 mg/mL Nexterone IV (PVC-free, lower hypotension risk) | Oral maintenance 400 mg/d typical; higher in refractory cases | Oral • IV | IV: minutes; oral: weeks to load | Weeks after discontinuation (extremely long half-life) | ~58 days (parent); ~61 days (desethylamiodarone, active metabolite)'"`UNIQ--ref-00000CB3-QINU`"' | ~50% (oral; highly variable)'"`UNIQ--ref-00000CB4-QINU`"' | Generally avoided; fetal goiter/hypothyroidism risk (iodine load). Used only for life-threatening arrhythmia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for pulmonary toxicity (interstitial pneumonitis, fibrosis), hepatotoxicity, and proarrhythmia'"`UNIQ--ref-00000CB5-QINU`"' | |||
| Amitriptyline (edit) | Amitriptyline (hydrochloride) | Elavil (US brand discontinued; generic widely available), Endep, Tryptizol | [[:Category:Tricyclic antidepressants|Tricyclic antidepressant (TCA)]] • [[:Category:Antidepressants|Antidepressant]] • [[:Category:Migraine prophylactics|Migraine prophylactic]] • [[:Category:Neuropathic pain medicines|Neuropathic pain medicine]] | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' | Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply) | Tablets 10, 25, 50, 75, 100, 150 mg | 300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling | Oral | Sleep effect from first dose; analgesic and migraine-prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks | 24 hours (HS dosing) | Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"' | ~50% (oral)'"`UNIQ--ref-00000027-QINU`"' | Older agent with substantial use experience; observational signals not clearly causal.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' | |||
| Amlodipine (edit) | Amlodipine | Norvasc, Katerzia | [[:Category:Calcium_channel_blockers|Calcium channel blocker]] • [[:Category:Antihypertensives|Antihypertensive]] • [[:Category:Antianginals|Antianginal]] | '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. | '"`UNIQ--vote-00000075-QINU`"', '"`UNIQ--vote-00000076-QINU`"', '"`UNIQ--vote-00000077-QINU`"' | 2.5-5 mg PO once daily; titrate to 10 mg/d | 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension | 10 mg/d | Oral | BP effect within 24 hours; full effect at 1-2 weeks (long half-life) | 24 hours | 30-50 hours'"`UNIQ--ref-00000078-QINU`"' | 64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' | Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | ||
| Amobarbital (edit) | Amobarbital | Amytal | Barbiturate | ||||||||||||||
| Amoxapine (edit) | Amoxapine | TCA • Antidepressant | Serotonin and norepinephrine reuptake inhibitor | ||||||||||||||
| Amoxicillin (edit) | Amoxicillin | Amoxil, Trimox, Moxatag; mostly prescribed generically | [[:Category:Penicillins|Penicillin]] • [[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] • [[:Category:Aminopenicillins|Aminopenicillin]] | '"`UNIQ--vote-00000199-QINU`"' Extends ampicillin's spectrum with better oral bioavailability. Susceptible to β-lactamases; clavulanate co-administration restores activity against many resistant organisms'"`UNIQ--ref-0000019A-QINU`"'. | '"`UNIQ--vote-0000019B-QINU`"', '"`UNIQ--vote-0000019C-QINU`"', '"`UNIQ--vote-0000019D-QINU`"', '"`UNIQ--vote-0000019E-QINU`"', '"`UNIQ--vote-0000019F-QINU`"', '"`UNIQ--vote-000001A0-QINU`"' | 500 mg PO TID or 875 mg PO BID for most indications; 80-90 mg/kg/d divided BID in pediatric otitis media | 250 mg, 500 mg capsules; 500 mg, 875 mg tablets; 125, 200, 250, 400 mg/5 mL oral suspension; 775 mg ER; 50 mg/mL drops | 3 g/d typical; higher in severe infections under specialist guidance | Oral | Peak plasma at 1-2 hours; clinical effect within 24-72 hours | ~8 hours per dose | 1-1.3 hours'"`UNIQ--ref-000001A1-QINU`"' | 75-90% (oral; minimally affected by food)'"`UNIQ--ref-000001A2-QINU`"' | Generally considered safe; widely used in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | ||
| AMT (edit) | aMT | Research material • Tryptamine • Stimulant | Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor | ||||||||||||||
| Anadenanthera colubrina (edit) | Anadenanthera colubrina | Source of DMT-class tryptamines | |||||||||||||||
| Anadenanthera peregrina (edit) | Anadenanthera peregrina | Source of [[DMT]], bufotenine, and 5-MeO-DMT | |||||||||||||||
| Anastrozole (edit) | Anastrozole | Arimidex | [[:Category:Aromatase_inhibitors|Aromatase inhibitor (non-steroidal)]] • [[:Category:Antineoplastics|Antineoplastic]] • [[:Category:Endocrine_therapy|Endocrine therapy]] | '"`UNIQ--vote-00000B61-QINU`"', '"`UNIQ--vote-00000B62-QINU`"', '"`UNIQ--vote-00000B63-QINU`"' | 1 mg PO once daily | 1 mg tablets | 1 mg/d | Oral | Estrogen suppression within days; clinical effect over months | 24 hours | ~50 hours'"`UNIQ--ref-00000B64-QINU`"' | High (oral; not significantly affected by food)'"`UNIQ--ref-00000B65-QINU`"' | Contraindicated in pregnancy (only used in postmenopausal women); D class historically.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> | [[USLegal:Prescription only|Rx-only]] in US | |||
| Aniracetam (edit) | Aniracetam | Nootropic • Racetam | AMPA receptor positive allosteric modulator | ||||||||||||||
| APICA (edit) | APICA | Synthetic cannabinoid • Research material | CB1/CB2 agonist | ||||||||||||||
| Apixaban (edit) | Apixaban | Eliquis | [[:Category:Anticoagulants|Anticoagulant]] • [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] • [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] | '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. | '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' | NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID | 2.5 mg, 5 mg tablets | 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID | Oral | Peak anticoagulant effect 3-4 hours | 12 hours | ~12 hours'"`UNIQ--ref-000001FB-QINU`"' | ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' | [[USLegal:Prescription only|Rx-only]] in US | |||
| Apomorphine (edit) | Apomorphine | Apokyn | Antiparkinsonian • Dopamine agonist | Non-selective dopamine receptor agonist | |||||||||||||
| Aripiprazole (edit) | Aripiprazole | Abilify (oral), Abilify Maintena (monthly IM LAI), Aristada (aripiprazole lauroxil IM LAI), Abilify Asimtufii (bi-monthly IM LAI), Abilify MyCite (digital ingestion sensor) | [[:Category:Neuroleptics|Neuroleptic]] • [[:Category:Atypical neuroleptics|Atypical neuroleptic]] • [[:Category:Third-generation neuroleptics|Third-generation neuroleptic]] • [[:Category:Mood stabilizers|Mood stabilizer]] | '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' | Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap | Tablets 2, 5, 10, 15, 20, 30 mg; ODT 10, 15 mg; oral solution 1 mg/mL; acute IM injection 9.75 mg/1.3 mL; Maintena LAI 300, 400 mg monthly; Aristada LAI 441, 662, 882, 1064 mg (4-8 week dosing); Asimtufii bi-monthly | 30 mg/day (adult schizophrenia); 15 mg/day (MDD adjunct) | Oral • intramuscular (acute and long-acting) | Neuroleptic effect emerges over days to weeks; activation symptoms (akathisia, insomnia) often within days | 24 hours (oral); 4-8 weeks (LAI) | ~75 hours (long, accumulates over weeks)'"`UNIQ--ref-00000023-QINU`"' | ~87% (oral)'"`UNIQ--ref-00000024-QINU`"' | Limited human data; signal for neonatal extrapyramidal symptoms and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |